Mirtazapine

證據等級: L5

預測適應症: 3 個

Mirtazapine: From Depression to Ohdo Syndrome and Variants

One-Sentence Summary

Mirtazapine is a NaSSA-class antidepressant (noradrenergic and specific serotonergic antidepressant), historically used to treat depression. The TxGNN model predicts a possible role in Ohdo syndrome and variants, a rare developmental chromatin-remodeling disorder — but this prediction is currently supported by 0 clinical trials and 0 publications, and is model-inference only.

Quick Overview

Item	Content
Original Indication	Not specified in the current evidence pack. Known clinical class: NaSSA antidepressant (depression) — MOA and indication data are a confirmed gap (DG002)
Predicted New Indication	Ohdo syndrome and variants
TxGNN Prediction Score	99.42%
Evidence Level	L5 (no clinical trials or literature; model prediction only)
Germany Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (DG002, High severity). Mirtazapine is known to act as a NaSSA — antagonizing α2-adrenergic autoreceptors/heteroreceptors to increase norepinephrine and serotonin release, along with 5-HT2/5-HT3 antagonism (efficacy in depression) and H1 antagonism (sedation, appetite stimulation).

Ohdo syndrome and its variants (including blepharophimosis–intellectual disability syndrome, Ohdo type, ranked #2 in this pack) are rare congenital disorders caused by mutations in genes such as KAT6B and MED12, with core pathology in chromatin remodeling and transcriptional regulation. This is mechanistically distinct from mirtazapine's monoaminergic pharmacology — there is no direct etiological link. Any theoretical benefit would be limited to symptomatic management of sleep disturbance or behavioral issues that can accompany the syndrome, not disease modification.

The third-ranked prediction, benign paroxysmal torticollis of infancy, is thought to involve channelopathy-related mechanisms (e.g., CACNA1A) rather than monoamine dysregulation. While mirtazapine has occasional off-label use in migraine prevention via 5-HT2/3 and α2 pathways, this indication concerns an infant population with no pediatric safety data available here.

Overall, all three predictions in this pack appear to reflect disease-ontology similarity within the TxGNN knowledge graph (the top two are subtypes of the same syndrome) rather than a substantiated pharmacological rationale.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Germany Market Information

Mirtazapine is currently not marketed in Germany under this evidence pack (0 authorizations on file, no license records available).

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug interaction data are all marked as data gaps in this evidence pack — see DG001, Blocking severity.)

Conclusion and Next Steps

Decision: Hold

Rationale: All three predicted indications carry L5 evidence (no clinical trials, no literature) with a weak or absent mechanistic link to mirtazapine's known pharmacology, and the top two predictions likely reflect disease-ontology proximity rather than true drug-disease relevance. A blocking safety data gap (TFDA label warnings/contraindications) also prevents any S1 safety pre-assessment.

To proceed, the following is needed:

TFDA label PDF (warnings, contraindications) to close DG001 (Blocking)
Confirmed mechanism of action via DrugBank API to close DG002 (High)
Original indication/regulatory history (currently absent from taiwan_regulatory.licenses)
Any preclinical, case-report, or mechanistic literature specifically linking mirtazapine to chromatin-remodeling disorders or infant paroxysmal syndromes, given the current absence of supporting evidence
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.